Center for Animal Resources and Education, Cornell University, Ithaca, New York;, Email:
Center for Animal Resources and Education, Cornell University, Ithaca, New York.
J Am Assoc Lab Anim Sci. 2021 Mar 1;60(2):221-228. doi: 10.30802/AALAS-JAALAS-20-000064. Epub 2021 Feb 25.
Due to their effective analgesic properties, opioids are worthy of consideration for pain management in rabbits. However, this class of drugs causes undesirable effects including reduced gastrointestinal (GI) motility, reduced fecal output, and delays GI transit times and thus increases the risk of GI stasis. The risk of stasis discourages the use of opioids in rabbits, which could affect animal welfare. Gastroprokinetic agents such as cisapride are effective in promoting gastric emptying in many species, but whether this effect occurs in rabbits is unknown. This study assessed the efficacy of cisapride when administered as a single agent and in combination with buprenorphine in rabbits; efficacy was assessed by measuring GI transit times, fecal output, body weight, and food and water intake. Female New Zealand White rabbits ( = 10) were studied in a crossover, randomized design and received either vehicle and buprenorphine, cisapride and saline, cisapride and buprenorphine, or vehicle and saline (control) every 8 h for 2 d. Rabbits were anesthetized and administered radio-opaque, barium-filled spheres via orogastric tube. Feces was assessed via radiography for detection of the barium-spheres to determine GI transit time. GI transit time was significantly longer in buprenorphine groups than in control groups, regardless of the use of cisapride. Fecal output and food and water intake were lower for buprenorphine groups than control groups. Cisapride did not significantly alter GI transit, fecal output, or food and water intake. In addition, treatment group did not significantly affect body weight. In conclusion, buprenorphine treatment (0.03 mg/kg TID) prolonged GI transit time and reduced fecal output and food and water consumption in rabbits. Coadministration of buprenorphine and cisapride (0.5 mg/kg) did not ameliorate these effects, and the administration of cisapride at this dose did not appear to affect GI motility in female rabbits.
由于具有有效的镇痛特性,阿片类药物在兔子的疼痛管理中值得考虑。然而,这类药物会引起不良反应,包括降低胃肠道(GI)蠕动、减少粪便排出量,并延迟 GI 转运时间,从而增加 GI 停滞的风险。停滞的风险阻碍了阿片类药物在兔子中的使用,这可能会影响动物福利。西沙必利等胃动力药物在许多物种中有效地促进胃排空,但这种作用是否发生在兔子中尚不清楚。本研究评估了西沙必利作为单一药物和与丁丙诺啡联合使用在兔子中的疗效;通过测量 GI 转运时间、粪便排出量、体重以及食物和水的摄入量来评估疗效。雌性新西兰白兔(n = 10)进行了交叉、随机设计研究,每 8 小时接受一次载体和丁丙诺啡、西沙必利和生理盐水、西沙必利和丁丙诺啡或载体和生理盐水(对照),持续 2 天。兔子被麻醉并通过口腔胃管给予放射性不透射线的钡填充球体。通过放射照相术评估粪便以检测钡球,以确定 GI 转运时间。与对照组相比,丁丙诺啡组的 GI 转运时间明显更长,无论是否使用西沙必利。丁丙诺啡组的粪便排出量和食物与水的摄入量均低于对照组。西沙必利对 GI 转运、粪便排出量或食物和水的摄入量没有显著影响。此外,治疗组对体重没有显著影响。总之,丁丙诺啡(0.03 mg/kg TID)治疗延长了 GI 转运时间,并减少了兔子的粪便排出量和食物与水的摄入量。丁丙诺啡和西沙必利(0.5 mg/kg)的联合给药并不能改善这些作用,并且在该剂量下给予西沙必利似乎不会影响雌性兔子的胃肠道动力。